Navigation Links
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
Date:8/3/2009

nced cancer patients with solid tumors that have metastasized to the bone, and to patients with multiple myeloma, both groups who routinely suffer SREs," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "We are very encouraged by the overall strength of the data, which we will present in a scientific forum later this year. We are also looking forward to reviewing the results of a final SRE study, in patients with advanced prostate cancer, next year."

Bone metastases, the spread of tumors to the bone, are a serious concern for many advanced cancer patients. When cancer spreads to the bone, the growing cancer cells weaken and destroy the bone around the tumor. This damage can result in a number of serious bone complications, collectively called SREs.

Full safety and efficacy data will be submitted for presentation at an upcoming medical meeting in the second half of this year.

Study Design

This was an international Phase 3, randomized, doubleblind, active controlled study comparing denosumab with Zometa in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Patients enrolled in this event-driven study were randomized in a one-to-one ratio to receive either 120 mg of denosumab subcutaneously every four weeks (Q4W) or Zometa administered intravenously at a dose of 4 mg single, 15 minute infusion every four weeks.

In clinical trials thus far to test new medications for bone metastases, treatment success has been measured by whether the bone complications, or SREs, caused by the tumor are reduced or delayed. The primary and secondary endpoints of the denosumab bone metastases studies use a composite endpoint of four SREs - fracture, radiation to bone, surgery to bone, and spinal cord compression - to measure the effectiveness of denosumab versus Zomet
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... Creates New Tool That Increases Training Capability , World renown body ... called Zejax ( http://www.Zejax.com ), that dramatically increases a person’s training capability. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, ... Olympics World Games, the largest sports and humanitarian event in the world this year ... The World Games, held July 25 through August 2, 2015, benefited from the participation ...
(Date:7/30/2015)... ... , ... Quintessa Medical Spa is happy to offer patients the latest treatment ... for the elimination of excess tissue under the chin, referred to as submental fat. ... to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was approved by ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... on behalf of the New Jersey Department of Health, has received a $2.9 ... an agency of the U.S. Department of Health and Human Services (HHS). NJII ...
(Date:7/30/2015)... ... July 30, 2015 , ... Bird B Gone, the leader in bird control ... to repel pest birds from the AC units and ventilation systems on hospital ... toxoplasmosis, even the West Nile virus. When these droppings dry, the fine powder can ...
Breaking Medicine News(10 mins):Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2
... the air, indeed! Today, it has been revealed that deaths ... past decade// and we owe this development to better ... treatment measures. ,The data enabled by the government ... deaths since 1966 for those below 75 years of age. ...
... women with higher levels of Vitamin-E in their blood are ... ,Theresa O. Scholl and colleagues at the University of ... women and measured the plasma concentrations of alpha-tocopherol-one, a form ... pregnancy. ,They found the women who had ...
... Delhi Chief Minister Sheila Dikshit today inaugurated a new 120-bed ... at the Tihar Jail//, one of Asia’s biggest prisons having ... the jail hospital premises, was built at a cost of ... of its kind to be started in any jail in ...
... A team of University of California, San Diego physicists ... of blood vessels// in the brain that makes it ... of the puzzling damage to the brain’s gray matter ... ,In the study, published this week in the ...
... of us think of chromium as the shiny metal in ... the metal plays a crucial role in human health//, reports ... In rats, chromium deficiency leads to high cholesterol levels. In ... information, it’s too early to recommend chromium supplements for cholesterol. ...
... it’s our most vital organ, surprisingly little is ... makes it harder to uncover what’s gone awry ... brain-associated disorders, and ultimately, it often leaves physicians ... as Alzheimer’s and Parkinson’s disease, schizophrenia, attention deficit ...
Cached Medicine News:Health News:Bottleneck in Blood Supply Makes Brain Vulnerable to Strokes 2Health News:Bottleneck in Blood Supply Makes Brain Vulnerable to Strokes 3Health News:Chromium May Help Diabetes, Cholesterol, and Heart Disease 2Health News:Researchers Looking for Genes That Control the Brain 2
The 81130 Xenon AC/DC light source is the brightest, smallest transportable unit avaliable. The quck charge rechargable battery and low power consumption allows for 2 hours continuous use in the fie...
Tested by surgeons for functionality and ergonomy. Uses the Medifix C1301-1CCD camera head....
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 460 lines, NTSC output at 470 lines, focal length 30mm. 90mm length x 20mm diameter....
Large image and wide-angle design....
Medicine Products: